T cell

Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting

Retrieved on: 
fredag, april 8, 2022
MSD, Company, Abstract, Therapy, Cytokine, Syngenic, Private Securities Litigation Reform Act, Pembrolizumab, Protein engineering, Lymphoma, IND, AACR, SEC, Tumor microenvironment, American Association, Ernest, Patient, IL-12, Cancer, U.S. Securities and Exchange Commission, CD8, Association, American Association for Cancer Research, T cell, COVID-19, GLOBE, Ring (novel series), Terminology, Convention center, Engineering, Merck, Security (finance), Vaccine, Pharmaceutical industry, Medical imaging, Immunotherapy, Neoplasm

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, today announced it presented promising preclinical data on its IL-2 and IL-12 INDUKINE™ molecules, WTX-124 and WTX-330, respectively, in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans.

Key Points: 
  • These data suggest our approach may overcome these limitations and address the shortcomings associated with current cytokine treatments.
  • Both data posters are now available online to AACR Annual Meeting attendees, and can be viewed in person between 1:30-5:00 PM CDT on Monday, April 11, during the AACR session PO.IM02.13, Immune Response to Therapies 1, Poster Section 37.
  • Werewolf is developing WTX-124 as a potential monotherapy or in combination with checkpoint inhibitors in multiple tumor types.
  • Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer.

Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate

Retrieved on: 
torsdag, april 7, 2022
Central, T cell, LinkedIn, WHO, Fever, Dengue fever, Public health, Coronavirus, Research, Egg, Prevalence, ATCC, Mosquito-borne disease, MHC, Safety, Infection, Twitter, Climate, Science, Drug discovery, Flaviviridae, CD8, Nociception, History, Collection, Vaccine, Yellow fever, Chikungunya

Emergex has a growing pipeline of innovative CD8+ T-Cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease.

Key Points: 
  • Emergex has a growing pipeline of innovative CD8+ T-Cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease.
  • Other programmes in development include vaccine candidates for universal (pandemic) Influenza, Chikungunya, and a booster vaccine for Yellow Fever.
  • With potential stability at ambient temperatures, the vaccine candidates as intended reduce the burden and logistics of vaccine administration.
  • Yellow Fever is a severe, potentially fatal, mosquito-borne disease endemic to tropical and subtropical regions of Africa, Central and South America.

Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting

Retrieved on: 
fredag, april 8, 2022
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Cancer, WT, IND, AACR, Research, American Association, Neoplasm, Biopharmaceutical, T cell, CD22, Lymphatic system, Association, American Association for Cancer Research, Safety, CD19, Elpis, IL2, NK, Engineering, Patient, Cryptocurrency, Vaccine

Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, today presented two posters at the American Association for Cancer Research (AACR) Annual Meeting, occurring April 8-13, 2022.

Key Points: 
  • Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, today presented two posters at the American Association for Cancer Research (AACR) Annual Meeting, occurring April 8-13, 2022.
  • We are excited to showcase our latest breakthrough research.
  • Elpis Biopharmaceuticals is engineering and developing multifunctional immunotherapies, which modulate disease biology with precision and safety to overcome cancer resistance.
  • Elpis is headquartered in Lexington, MA, with research labs in the U.S. and China.

OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine

Retrieved on: 
onsdag, mars 16, 2022
Â, Immunotherapy, OSE, Peptide, GLOBE, Patient, Immunity, Membrane protein, SARS, Fortification, Partnership, Immunodeficiency, Therapy, Boehringer Ingelheim, MERS, COVID-19, Large-cell lung carcinoma, Epitope, Capsid, Degenerative disease, Transplant, Week, IND, CD8, Clinical trial, Pancreatic cancer, ISIN, Cancer, Tissue, Severe acute respiratory syndrome coronavirus 2, Mnemos EP, Mab, Inflammation, Lung, PD-1, Nivolumab, Immune system, Longevity, Variants of SARS-CoV-2, IL-7, Coronavirus, Autoimmune disease, Ulcerative colitis, T cell, Vaccine, Pharmaceutical industry, Omicron, Delta

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.

Key Points: 
  • Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.
  • NANTES, France, March 16, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announces positive analysis of the long-term immune T cell responses of CoVepiT, its prophylactic vaccine candidate against COVID-19, with positive immunological results obtained at 6 months on T cell memory response in the vaccinated subjects.
  • This long term positive immune response is of strong interest (2) as more multispecific memory T cells are expected to be efficient for immunocompromised patients in case of any new emerging coronavirus or variants of concern.
  • In preclinical testing, CoVepiT demonstrated the ability to activate T cell defenses through CD8 T-cell multi-epitope responses for long-term T memory cell immunity.

Global Cell Therapy Manufacturing Markets, Competition, Forecast and Opportunities, 2026: Focus on T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies - ResearchAndMarkets.com

Retrieved on: 
onsdag, mars 16, 2022
Health, General Health, Degenerative disease, Human, Cell, Immunity, Patient, Vaccine, T cell, Therapy, Obesity, COVID-19, CAGR, Application, Prevalence, Cancer, Growth, Death, Diabetes, Medical imaging, Pet, Pharmaceutical industry, Medical device, Fine chemical

The "Global Cell Therapy Manufacturing Market, By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell, By Scale of Operation, By Source, By Application, By End User, By Region, Competition Forecast and Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cell Therapy Manufacturing Market, By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell, By Scale of Operation, By Source, By Application, By End User, By Region, Competition Forecast and Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cell Therapy Manufacturing Market is segmented by therapy, source of cell, scale of operation, source, application, end-user, company, and regional distribution.
  • To classify and forecast the Global Cell Therapy Manufacturing Market based on therapy, source of cell, scale of operation, source, application, end-user, company, and regional distribution.
  • To identify key sustainable strategies adopted by the market players in the Global Cell Therapy Manufacturing Market.

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
måndag, januari 10, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, International, T cell, Advertising, Genetics, Environment, USD, Hematology, Vaccine, Conference, Probability, IFRS, Safety, Disease, Acceleration, Thrombotic thrombocytopenic purpura, JPY, FDA, Takeda Pharmaceutical Company, Failure, Partnership, TSE, Annual report, Technical, U.S. Securities and Exchange Commission, PTRS, TTP, Patient, EBITDA, Dengue fever, Increment, Growth, Review, ADAMTS13, Investment, Acquisition, Income, R, 10B, TAK, International Financial Reporting Standards, Quality of life, Projection, Pharmaceutical industry, Renewable energy, Cryptocurrency, Neuroscience, Takeda, Gastroenterology

Presenting at the 40th Annual J.P. Morgan Healthcare Conference, Christophe Weber, Takedas President and Chief Executive Officer, reinforced the mid-term revenue growth potential of its 14 global brands.

Key Points: 
  • Presenting at the 40th Annual J.P. Morgan Healthcare Conference, Christophe Weber, Takedas President and Chief Executive Officer, reinforced the mid-term revenue growth potential of its 14 global brands.
  • Over the past decade, we have reinvented ourselves into a top-tier global company positioned for strong growth through innovation.
  • The company also reviewed assumptions for Entyvio (vedolizumab) biosimilars, and is no longer expecting entry of biosimilars when data exclusivity expires.
  • Slides from the J.P. Morgan Healthcare Conference presentation and a link to the audio webcast can be accessed on Takedas website at: https://www.takeda.com/investors/ir-events/ .

Tevogen Bio Presents Data Detailing Immunologic Escape in SARS-CoV-2 Variants Underscoring Criticality of its T Cell Target Tuning Technology and Investigational COVID-19 therapy at ASH 2021

Retrieved on: 
tisdag, december 14, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Hepatitis B, Annual general meeting, Omicron, NIH, A24, FDA, Cervical cancer, Company, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Cancer, Cell, Immunity, Bio, Technology, Genome, Immunodominance, T cell, COVID-19, Professor, Degenerative disease, Sensitization, Hepatitis, Patient, Therapy, Immune system, Department, Exposition, Infection, CTLS, Efficiency, Immunology, Medicine, Mutation, Epitope, ASH, Thomas Jefferson University, NSCLC, Peptide, Oncology, CTL, Society, Vaccine, Delta, TVGN-489, Tevogen Bio, TVGN-489, TEVOGEN BIO

TVGN-489s in vitro pattern of response illustrates the importance of these issues in cytotoxic T cell therapy.

Key Points: 
  • TVGN-489s in vitro pattern of response illustrates the importance of these issues in cytotoxic T cell therapy.
  • TVGN-489 is a clinical grade product consisting of highly enriched, highly potent CD8+ CTLs recognizing peptides derived from COVID-19.
  • The cells are derived from healthy donors who have recovered from a prior COVID-19 infection.
  • This peptide, from ORF1ab (not Spike) is lost in 93% of the Delta variant isolates reported to the NIH-NLM database.

Dr. Lindee Goh of Tapestry Networks and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center, Join Tevogen Bio’s Innovation and Public Health Advisory Council

Retrieved on: 
måndag, december 6, 2021
Biotechnology, Health, Professional Services, Clinical Trials, Human Resources, Patient, NSCLC, MIT, Cervical cancer, Cancer, Loudon County, Tennessee, Technology, T cell, Company, MIT Center for Digital Business, Biology, Health, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Solution, Thomas Jefferson University, Therapy, Hepatitis, COVID-19, Delta Omega, Omicron, Howard Hughes Medical Institute, Hepatitis B, EMS, CTL, Massachusetts Institute of Technology, American College, Efficiency, FDA, Infection, Medicine, Degenerative disease, Bio, Covenant Health, Pharmaceutical industry

Tevogen Bio, a clinical stage biotechnology company, announces the appointments of Dr. Lindee Goh who leads Tapestry Networks healthcare practice and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center in Tennessee, to its Innovation and Public Health Advisory Council (IPHAC).

Key Points: 
  • Tevogen Bio, a clinical stage biotechnology company, announces the appointments of Dr. Lindee Goh who leads Tapestry Networks healthcare practice and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center in Tennessee, to its Innovation and Public Health Advisory Council (IPHAC).
  • Lindee Goh, Ph.D., leads Tapestry Networks healthcare practice, working with public and private sector leaders to develop effective strategies to improve clinical outcomes while fostering sustainable healthcare innovation.
  • Jeffrey Feike is President and Chief Administrative Officer of Fort Loudoun Medical Center, a member of Covenant Health, in eastern Tennessee.
  • The current pandemic is a public health crisis that needs novel solutions which require disruptive innovation, new biopharmaceutical business models, and a caring spirit.

Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in Oncology

Retrieved on: 
måndag, december 6, 2021
Cancer, Safety, G17, MD, Health, Tumor microenvironment, T cell, Therapy, Diphtheria, PAS, Gastrointestinal cancer, Mouse, Neoplasm, GLOBE, Polyclonal antibodies, Programmed cell death protein 1, Esophageal cancer, Antibody, Medicine, Fibrosis, Stomach, Georgetown University Medical Center, Growth, Vaccine, Medical imaging, Palladium

Tumor growth was significantly slower than controls in PAS-treated mice, and tumor growth rate was decreased even more in combination-treated mice.

Key Points: 
  • Tumor growth was significantly slower than controls in PAS-treated mice, and tumor growth rate was decreased even more in combination-treated mice.
  • There were no metastases in any of the mice treated with PAS either alone or in combination with PD-1 Ab.
  • Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal.
  • Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program.

Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations

Retrieved on: 
torsdag, december 2, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patient, NSCLC, Cervical cancer, Cancer, Oncology, Technology, NIH, T cell, Company, SARS-COV-2, CTLS, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Thomas Jefferson University, Therapy, Hepatitis, COVID-19, Professor, Hepatitis B, Research, Immunity, Mutation, CTL, Efficiency, FDA, Epitope, Infection, Immunotherapy, Immune system, Medicine, Degenerative disease, Bio, Department, Vaccine, TVGN-489, Tevogen Bio, TVGN-489, TEVOGEN BIO

A comprehensive review, completed by its preeminent research team, finds the targets of TVGN-489 are not impacted by known Omicron mutations.

Key Points: 
  • A comprehensive review, completed by its preeminent research team, finds the targets of TVGN-489 are not impacted by known Omicron mutations.
  • We are deeply concerned about the recently reported Omicron variants worrisome immune escape potential and transmissibility.
  • Our research team has reviewed all the mutations present in the Omicron variant and ascertained that TVGN-489s targets have not been affected.
  • Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises.